Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Posted by on Oct 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The review aimed to assess chemotherapy-free treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL).   Some background Standard therapy for slow-growing non-Hodgkin lymphoma (NHL) such as FL and MZL involves immunochemotherapy (ICT). ICT combines immunotherapy and chemotherapy treatments. However, many patients...

Read More

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...

Read More

Which type of stem cell transplant is best for patients with T-cell lymphoma?

Which type of stem cell transplant is best for patients with T-cell lymphoma?

Posted by on Sep 26, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use of two types of stem cell transplant (SCT) in the treatment of T-cell lymphoma.  It found that both haploidentical and umbilical cord blood SCT were good options for these patients.  Some background T-cell lymphoma is a cancer affecting a certain type of blood cell called T-cells. T-cells are...

Read More

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...

Read More

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...

Read More

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Read More

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to...

Read More

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Read More

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years. For a long...

Read More